-
Dtsch Arztebl Int: Increased risk of skin tumors and infectious diseases after organ transplantation?
Time of Update: 2022-01-23
In a retrospective study published today in Dtsch Arztebl Int, researchers selectively reviewed publications obtained through a PubMed search discussing the incidence and major risk factors of skin tumors and skin infections in immunosuppressed patients .
-
European Radiology: Lung-RADS classification application of computer-aided diagnosis in CT screening of lung cancer
Time of Update: 2022-01-23
diagnosisRecently, a study published in the journal European Radiology evaluated the impact of CAD on inter-reader consistency in pulmonary RADS classification, providing a guarantee for the automatic detection and risk assessment of pulmonary nodules, and improving the consistency of image interpretation.
-
BMC Cancer: Prospective study with up to 10 years of follow-up confirms that younger women with non-metastatic breast cancer have worse prognosis
Time of Update: 2022-01-23
In conclusion, this prospective study confirms that young age (<40 years) is a poor prognostic factor in patients with non-metastatic breast cancer .
In conclusion, this prospective study confirms that young age (<40 years) is a poor prognostic factor in patients with non-metastatic breast cancer .
-
Thorac Cancer: Retrospective analysis of factors associated with long-term survival in NSCLC patients treated with nivolumab
Time of Update: 2022-01-23
Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab.
Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab.
-
J Immunother Cancer: Research by Prof. Xiaohua Wu's team of Fuzhu shows that camrelizumab combined with famitinib can be an effective treatment for platinum-resistant recurrent ovarian cancer
Time of Update: 2022-01-23
Secondary endpoints include disease control rate (DCR), duration of response (DoR), treatment-to-response (TTR), progression-free survival (PFS), overall survival (OS), 12-month OS rate and safety .
Secondary endpoints include disease control rate (DCR), duration of response (DoR), treatment-to-response (TTR), progression-free survival (PFS), overall survival (OS), 12-month OS rate and safety .
-
CA: Latest Cancer Statistics: U.S. Cancer Death Rates Down 32% From Peak, Lung Cancer Survival Rates Improve, Breast Cancer Incidences Rise Slowly
Time of Update: 2022-01-21
In recent years, an increasing number of lung cancer patients have been diagnosed at an early stage of the cancer, leading to a longer life expectancy .
-
The Hepatobiliary Surgery Department of the East Branch of the First Affiliated Hospital of Xi'an Jiaotong University successfully resected a huge liver tumor with a diameter of 25 cm
Time of Update: 2022-01-21
Associate Professor Sha Huanchen, director of the Hepatobiliary Surgery Department, was preparing to go to the operating room to carry out emergency treatment for a patient with a huge liver tumor.
-
Science Advances: Zhang Xu et al. of Jiangsu University develop engineered exosomes to treat cancer
Time of Update: 2022-01-21
Science Advances Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapyThis study developed a simple and efficient engineered neutrophil-derived exosomes (N-Ex) and neutrophil-derived nanovesicles (NNV) as a safe and effective drug for tumor therapy.
-
European Radiology: Deep learning makes it possible to quickly classify bone tumors on plain radiographs!
Time of Update: 2022-01-21
Recently, a study published in the journal European Radiology evaluated the ability of DL in differentiating benign, malignant and intermediate bone tumors , and compared DL with the diagnostic level of radiologists for rapid and accurate clinical evaluation of bone tumors.
-
Will PD-1 inhibitors continue treatment after 1 year of advanced lung cancer?
Time of Update: 2022-01-09
CheckMate153 study Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153 The CheckMate153 study is the first randomized clinical study to evaluate the duration of PD-1 inhibitor treatment .
-
Cancer Cell Fudan University multi-unit cooperation, Fan Jia/Zhou Hu/Gao Daming/Gao Qiang jointly draw the multi-omics molecular feature panorama of intrahepatic cholangiocarcinoma
Time of Update: 2022-01-09
On December 30, 2021, Jia Fan, Gao Qiang, Fudan University, Zhou Hu, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Gao Daming, the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, published a joint communication online in Cancer Cell entitled "Proteogenomic characterization identifies clinically relevant subgroups of" Intrahepatic cholangiocarcinoma" research paper, which used paired tumors and adjacent liver tissues from 262 patients to perform protegenomic characterization of intrahepatic cholangiocarcinoma (iCCA) .
-
The first domestic CDK4/6 inhibitor Dulceli was approved for marketing; probiotics are not good for melanoma immunotherapy?
Time of Update: 2022-01-09
Frontier: The latest version of the National Medical Insurance Catalogue took effect, Zebutinib was once again reduced in price, and the lowest mid-month treatment cost for similar BTK 01JAMA Oncol: Gonadotropin The effect of releasing hormone analogues on ovarian function in premenopausal breast cancer patients The results of studies on the use of gonadotropin releasing hormone analogues (GnRHa) to protect ovarian function have been mixed .
-
Scientists in Nature sub-publish found that super nanoparticles other than exosomes are rich in disease biomarkers and therapeutic targets.
Time of Update: 2022-01-09
Professor Robert Coffey of Vanderbilt University Medical Center is a well-known intestinal tumor expert and is actively exploring whether the detection of Supermeres in the blood can achieve earlier diagnosis and treatment of diseases .
-
For the nation, anti-tumor article takes stock of the 2021 Anlotinib & Paimrizumab blockbuster study (part 1)
Time of Update: 2022-01-09
Efficacy and safety of anlotinib combined with docetaxel in the treatment of advanced NSCLC that has failed the previous immune checkpoint PD-1 inhibitor treatment: a review of the results of a phase I/II study: median PFS in enrolled patients It was 7.
-
Professor Xu Ruihua: Ten important advances in clinical research on digestive system tumors in 2021
Time of Update: 2022-01-09
1. PD-1 monoclonal antibody combined with chemotherapy first-line treatment significantly improves patient survival KEYNOTE-590 is a randomized, controlled, double-blind, global 3 Phase trial (73% of patients with esophageal squamous cell carcinoma [ESCC]) [1] .
-
BMJ: Pathological complete remission should not be used as the primary endpoint of breast cancer neoadjuvant treatment studies
Time of Update: 2022-01-09
*Only for medical professionals to read for reference, 1 minute a day, to give you professional "talking information" in the tumor circle! (If you need the original text of the literature, you can ad
-
Progress in Macrophage Tumor Immunotherapy
Time of Update: 2022-01-09
Through innate immune cell therapy, the development of effective phagocyte targets and the search for new innate immune checkpoints are important strategies to improve the response rate of tumor immunotherapy .
-
Sub-Journal of "Cell": This bacteria can really fight cancer!
Time of Update: 2022-01-09
Recently, an article published on Cancer Cell proposed , A kind of probiotics and their metabolites that naturally exist in our intestines-Lactobacillus reuteri and Reuterin, can also effectively inhibit the development of colorectal cancer (CRC) [1 ] .
-
Colorectal cancer (CRC) monoclonal antibody, double antibody and CAR-T therapy
Time of Update: 2022-01-09
A phase II trial study showed that cetuximab has moderate anti-tumor activity once a week intravenously, and it is well tolerated in patients with CRC who are refractory to chemotherapy .
-
[Research] The mechanism that destroys the proliferation of cancer cells and induces their death—bringing new cancer treatment strategies
Time of Update: 2022-01-09
Studies have found that autophagy regulation is a new treatment strategy for cancer: drugs that induce high levels of autophagy can cause the collapse of tumor cells and the activation of apoptotic cell death programs .